BRPI0820068B8 - uso de cepa de levedura e/ou de uma composição compreendendo cepa de levedura para preparação de um medicamento - Google Patents

uso de cepa de levedura e/ou de uma composição compreendendo cepa de levedura para preparação de um medicamento

Info

Publication number
BRPI0820068B8
BRPI0820068B8 BRPI0820068A BRPI0820068A BRPI0820068B8 BR PI0820068 B8 BRPI0820068 B8 BR PI0820068B8 BR PI0820068 A BRPI0820068 A BR PI0820068A BR PI0820068 A BRPI0820068 A BR PI0820068A BR PI0820068 B8 BRPI0820068 B8 BR PI0820068B8
Authority
BR
Brazil
Prior art keywords
yeast strain
composition
yeast
medicament
preparing
Prior art date
Application number
BRPI0820068A
Other languages
English (en)
Inventor
Sivignon Adeline
Darfeuille-Michaud Arlette
Poulain Daniel
Pignede Georges
Simon Jean-Luc
Vandekerckove Pascal
Desreumaux Pierre
Original Assignee
Lesaffre & Cie
Univ Dauvergne Clermont 1
Univ Du Droit Et De La Sante Lille 2
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0801342A external-priority patent/FR2928652B1/fr
Application filed by Lesaffre & Cie, Univ Dauvergne Clermont 1, Univ Du Droit Et De La Sante Lille 2 filed Critical Lesaffre & Cie
Publication of BRPI0820068A2 publication Critical patent/BRPI0820068A2/pt
Publication of BRPI0820068B1 publication Critical patent/BRPI0820068B1/pt
Publication of BRPI0820068B8 publication Critical patent/BRPI0820068B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/14—Yeasts or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/18—Baker's yeast; Brewer's yeast
    • C12N1/185—Saccharomyces isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/85—Saccharomyces
    • C12R2001/865—Saccharomyces cerevisiae

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Botany (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cosmetics (AREA)

Abstract

composição para nutrição e/ou animal, usos derivados e leveduras a invenção se relaciona a novas cepas de leveduras, a leveduras obtidas a partir destas cepas, a uma composição contendo pelo menos uma levedura saccharomyces cerevisiae e/ou derivados da levedura tendo um interesse particular como um aditivo alimentar e/ou probiótico ou com função alimentar e/ou nutricional ou nutracêutica e/ou com ingredientes funcionais e/ou cosmecêuticos e/ou ingrediente ativo em preparações farmacêuticas. a invenção também se relaciona ao uso da mesma em nutrição humana e/ou animal, ou para o tratamento ou prevenção de doenças inflamatórias.
BRPI0820068A 2007-12-26 2008-12-12 uso de cepa de levedura e/ou de uma composição compreendendo cepa de levedura para preparação de um medicamento BRPI0820068B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0760377 2007-12-26
FR0760377 2007-12-26
FR0801342 2008-03-12
FR0801342A FR2928652B1 (fr) 2008-03-12 2008-03-12 Composition pour l'alimentation humaine et/ou animale,ses utilisations,levures
PCT/FR2008/001729 WO2009103884A2 (fr) 2007-12-26 2008-12-12 Composition pour l'alimentation humaine et/ou animale, ses utilisations, levures

Publications (3)

Publication Number Publication Date
BRPI0820068A2 BRPI0820068A2 (pt) 2015-09-01
BRPI0820068B1 BRPI0820068B1 (pt) 2020-03-17
BRPI0820068B8 true BRPI0820068B8 (pt) 2021-07-27

Family

ID=40985983

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820068A BRPI0820068B8 (pt) 2007-12-26 2008-12-12 uso de cepa de levedura e/ou de uma composição compreendendo cepa de levedura para preparação de um medicamento

Country Status (24)

Country Link
US (1) US8476058B2 (pt)
EP (1) EP2227539B1 (pt)
JP (1) JP5497661B2 (pt)
KR (1) KR101654537B1 (pt)
CN (1) CN101918536B (pt)
AU (1) AU2008351156B2 (pt)
BR (1) BRPI0820068B8 (pt)
CA (1) CA2709850C (pt)
DK (1) DK2227539T3 (pt)
ES (1) ES2649914T3 (pt)
HR (1) HRP20171632T1 (pt)
HU (1) HUE034628T2 (pt)
IL (1) IL206110A (pt)
LT (1) LT2227539T (pt)
MX (1) MX2010007011A (pt)
MY (1) MY159379A (pt)
NO (1) NO2227539T3 (pt)
NZ (1) NZ586417A (pt)
PL (1) PL2227539T3 (pt)
RU (1) RU2490324C2 (pt)
SI (1) SI2227539T1 (pt)
TN (1) TN2010000239A1 (pt)
WO (1) WO2009103884A2 (pt)
ZA (1) ZA201003978B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2876798A1 (fr) * 2004-10-14 2006-04-21 Univ Clermont Auvergne Diagnostic et traitement de la maladie de crohn
NZ586417A (en) 2007-12-26 2012-07-27 Lesaffre & Cie Composition comprising saccharomyces cerevisiae yeast for human or animal probiotic or use in composition for treating hyperalgesia
FR2949043B1 (fr) * 2009-08-17 2013-05-17 Lesaffre & Cie Pate boulangere fermentee tolerante a l'appret
KR20180132958A (ko) * 2011-03-04 2018-12-12 라이온 가부시키가이샤 성장 호르몬 분비 촉진제
ITMI20111488A1 (it) * 2011-08-03 2013-02-04 Gnosis Spa Formulazioni comprendenti saccharomyces boulardii e superossido dismutasi (sod) per controllare l'obesita'
FR2993179B1 (fr) * 2012-07-13 2016-01-08 Lesaffre & Cie Levure saccharomyces cerevisiae pour prevenir et/ou traiter les mycoses vaginales
WO2015061798A2 (en) * 2013-10-25 2015-04-30 R.F. Technology Consultants, Inc. Compositions and methods comprising yeast organisms and lipid extracts thereof
US9730969B2 (en) 2015-11-06 2017-08-15 Mead Johnson Nutrition Company Nutritional compositions for promoting gut barrier function and ameliorating visceral pain
KR101837160B1 (ko) 2016-07-20 2018-03-09 서울대학교산학협력단 신균주 bt-sjp kctc12726bp 및 이의 용도
JPWO2018052082A1 (ja) * 2016-09-14 2019-06-24 株式会社Ｔｅｓホールディングス Ｌｉｎ２８ａ活性化剤及びその使用
US11523625B2 (en) 2017-08-07 2022-12-13 Techmix, Llc Feed supplement bolus with active yeast
CN109536370A (zh) * 2018-12-10 2019-03-29 浙江华康药业股份有限公司 一种体外发酵糖醇益生功能评价装置及方法
FR3089788B1 (fr) 2018-12-17 2020-12-18 Lesaffre & Cie Souche de levure Saccharomyces cerevisiae pour le traitement et/ou la prévention de candidoses oropharyngées
FR3090318A1 (fr) 2018-12-19 2020-06-26 Lesaffre Et Compagnie Souche Saccharomyces Cerevisiae var boulardii en Santé Orale
FR3096891B1 (fr) 2019-06-04 2022-05-13 Lesaffre & Cie Composition pour la prevention de la cystite simple et/ou recidivante
CN112273657A (zh) * 2019-07-22 2021-01-29 安琪酵母股份有限公司 用于预防或改善过敏性疾病的益生菌组合物、制法和应用
KR102275115B1 (ko) * 2019-10-16 2021-07-07 한국식품연구원 프로바이오틱 활성을 갖는 사카로마이세스 세레비지애 보울라디­０３ 신균주 및 이의 용도
FR3120789B1 (fr) 2021-03-16 2024-01-19 Lesaffre & Cie Inhibiteurs glycosidiques de levure
IL309521A (en) 2021-06-30 2024-02-01 Ab Mauri Uk Ltd Physiologically adapted yeast preparations and their uses
FR3134581A1 (fr) * 2022-04-15 2023-10-20 Lesaffre Et Compagnie Levure Saccharomyces cerevisiae et son utilisation pour améliorer la santé intestinale des animaux de compagnie.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1010770C2 (nl) * 1998-12-09 2000-06-13 Nutricia Nv Preparaat dat oligosacchariden en probiotica bevat.
RU2233320C2 (ru) * 2001-02-13 2004-07-27 Гриневич Владимир Борисович Способ получения биологически активного препарата, биологически активная добавка (бад) к пище пребиотического действия, приводящая к коррекции (нивелированию) метаболического синдрома и лекарственный препарат для регуляции микробиоценоза желудочно-кишечного тракта
EP1796700B1 (en) * 2004-08-23 2012-04-25 Bharat Biotech International Limited Eukaryotic based synergistic formulation for gastro-intestinal disorders
US7799328B2 (en) * 2004-12-23 2010-09-21 Biocodex Method for treating weight loss in patients suffering from inflammatory bowel diseases
US7498367B2 (en) * 2005-02-21 2009-03-03 Kerr Corporation Acid-tolerant dental composition
FR2928652B1 (fr) 2008-03-12 2013-11-15 Lesaffre & Cie Composition pour l'alimentation humaine et/ou animale,ses utilisations,levures
NZ586417A (en) 2007-12-26 2012-07-27 Lesaffre & Cie Composition comprising saccharomyces cerevisiae yeast for human or animal probiotic or use in composition for treating hyperalgesia

Also Published As

Publication number Publication date
CA2709850A1 (fr) 2009-08-27
MX2010007011A (es) 2010-10-13
RU2010131018A (ru) 2012-02-10
NO2227539T3 (pt) 2018-01-06
AU2008351156A1 (en) 2009-08-27
NZ586417A (en) 2012-07-27
MY159379A (en) 2016-12-30
JP5497661B2 (ja) 2014-05-21
IL206110A (en) 2013-07-31
JP2011509651A (ja) 2011-03-31
PL2227539T3 (pl) 2018-01-31
HRP20171632T1 (hr) 2017-12-15
ZA201003978B (en) 2012-02-29
WO2009103884A3 (fr) 2009-12-17
SI2227539T1 (en) 2018-03-30
KR101654537B1 (ko) 2016-09-06
KR20110066118A (ko) 2011-06-16
CA2709850C (fr) 2018-03-20
EP2227539A2 (fr) 2010-09-15
IL206110A0 (en) 2010-11-30
ES2649914T3 (es) 2018-01-16
CN101918536B (zh) 2013-07-03
US8476058B2 (en) 2013-07-02
CN101918536A (zh) 2010-12-15
US20100303778A1 (en) 2010-12-02
TN2010000239A1 (fr) 2011-11-11
RU2490324C2 (ru) 2013-08-20
AU2008351156B2 (en) 2013-10-17
BRPI0820068B1 (pt) 2020-03-17
BRPI0820068A2 (pt) 2015-09-01
EP2227539B1 (fr) 2017-08-09
DK2227539T3 (da) 2017-11-13
LT2227539T (lt) 2017-11-27
WO2009103884A2 (fr) 2009-08-27
HUE034628T2 (hu) 2018-02-28

Similar Documents

Publication Publication Date Title
BRPI0820068B8 (pt) uso de cepa de levedura e/ou de uma composição compreendendo cepa de levedura para preparação de um medicamento
Calixto-Campos et al. Vanillic acid inhibits inflammatory pain by inhibiting neutrophil recruitment, oxidative stress, cytokine production, and NFκB activation in mice
EP3626249A3 (en) Traditional chinese medicine healthcare preparation for fat elimination and weight reduction
BR112013016021A2 (pt) métodos e composições adequadas para gerenciar glicemia em animais
WO2011018501A3 (en) Composition including an unsaponifiable fraction
WO2010012408A3 (de) Mikroemulsion
WO2011106423A3 (en) Acai and iridoid based formulations
WO2011106417A3 (en) Garcinia mangostana l. and iridoid based formulations
Lu et al. Safety assessment of the fermented Phylloporia ribis (Lonicera japonica Thunb.) mycelia by oral acute toxicity study in mice and 90-day feeding study in rats
WO2011043631A3 (ko) 호장근 추출물, 이의 분획물 또는 스틸벤계 화합물을 포함하는 감기의 예방 및 치료용 약학 조성물
MX2022010964A (es) Composicion que comprende una avenantramida o un analogo de la misma con estabilidad mejorada.
BR112012012649A2 (pt) agente indutor de beta-defensina humana, formulação, e, usos de um agente indutor de beta-defensiva humana, e de pelo menos uma gordura ou óleo de um triglicerídeo de ácido graxo essencial ou de um derivado do mesmo.
EP2200574A1 (en) Novel use of panduratin derivatives or extract of kaempferia pandurata comprising the same
WO2019074617A3 (en) Neupanex ®: neuroprotective, neuroregenerational, & neurogenesis supporting supplement combination
WO2011052935A3 (ko) 토복령, 여주 및 동충하초 추출물을 유효성분으로 포함하는 혈당 강하용 조성물
Bok et al. Safety of 8-weeks oral administration of Arctium lappa L.
WO2011150229A3 (en) Dietary supplements containing extracts of cinnamon and methods of using same to promote enhanced sirtuin, cell and telomere integrity
WO2011141113A3 (de) Kombination aus vitamin k und nikotinamid
BRPI0910256A8 (pt) Usos de alternan como agente de texturização em ingredientes alimentícios, composições homogêneas, seus método de preparação e seus usos
MX2022010948A (es) COMPOSICIÓN O EXTRACTO DE AVENA QUE COMPRENDE AVENANTRAMIDA Y ß-GLUCANO.
Azeemi Effect of olive leaves extract on lipid profile, glucose and feed intake of Japanese quail
CO2024000323A2 (es) Composiciones de levadura fisiológicamente aceptables y usos de las mismas.
Singh et al. Biochemical estimation of primary metabolites of Phyla nodiflora L. Greene
KR101954076B1 (ko) 지모 추출물 및 홍해삼 추출물을 포함하는 아토피 피부 외용제 조성물
UA100402C2 (en) Composition for human and/or animal nutrition, uses thereof and yeasts

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: C12N 1/18; A61K 36/064; A23L 1/30.

Ipc: A61K 36/064 (2006.01), A23L 33/14 (2016.01), C12R

Ipc: A61K 36/064 (2006.01), A23L 33/14 (2016.01), C12R

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/12/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO